PLUR Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 geg. 2024 @ 16:30):

Stats
Dzisiejszy wolumen	384.00
Średni wolumen	28 146.00
Kapitalizacja rynkowa	33.68M
EPS	$0 ( 2024-05-08 )
Następna data zysków	( $0 ) 2024-06-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.350
ATR14	$0.181 (2.90%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-23	Franco-yehuda Chen	Buy	355 000	Common Stock
2024-01-23	Aberman Zami	Buy	44 100	Common Stock
2024-01-23	Birger Pinhas Doron	Buy	39 900	Common Stock
2024-01-23	Shemesh-rasmussen Maital	Buy	38 150	Common Stock
2024-01-23	Yanay Yaky	Buy	700 000	Common Stock

INSIDER POWER
99.92
Last 95 transactions
Buy: 8 548 074 \| Sell: 1 004 814

Pluri Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pluri Inc. Finanse

Annual	2023
Przychody:	$287 000
Zysk brutto:	$278 000 (96.86 %)
EPS:	$-6.18

FY	2023
Przychody:	$287 000
Zysk brutto:	$278 000 (96.86 %)
EPS:	$-6.18

FY	2022
Przychody:	$234 000
Zysk brutto:	$-41.36M (-17 674.79 %)
EPS:	$-1.270

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.770

Financial Reports:

No articles found.

Pluri Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Pluri Inc.

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Aktualne aktualizacje dla Pluri Inc. [PLUR]

Upcoming Earnings Alert

Pluri Inc. Options Data

Calls

Puts